757 results on '"Thompson, Kimberly M"'
Search Results
52. Optimal vaccine stockpile design for an eradicated disease: Application to polio
53. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative
54. Health economic analyses of secondary vaccine effects: a systematic review and policy insights
55. Measles
56. The risks, costs, and benefits of possible future global policies for managing polioviruses
57. Uncertainty and Sensitivity Analyses of a Dynamic Economic Evaluation Model for Vaccination Programs
58. Eradication versus control for poliomyelitis: an economic analysis
59. Parental survey of beliefs and practices about bathing and water safety and their children: Guidance for drowning prevention
60. Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019–2023
61. Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication
62. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response
63. Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options
64. Hypothetical emergence of poliovirus in 2020: part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions
65. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication
66. Quantifying the federal minimal risk standard: Implications for pediatric research without a prospect of direct benefit
67. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication
68. Content and ratings of teen-rated video games
69. Expert Review on Poliovirus Immunity and Transmission
70. Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine-Related Polioviruses
71. Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs)
72. Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs
73. Modeling Poliovirus Risks and the Legacy of Polio Eradication
74. Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses
75. Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control
76. Genetic testing for lung cancer risk: If physicians can do it, should they?
77. Economic Evaluation of the Benefits and Costs of Disease Elimination and Eradication Initiatives
78. Group Report: Developing an Eradication Investment Case
79. Using Models to Inform Policy: Insights from Modeling the Complexities of Global Polio Eradication
80. Body weight and water ingestion estimates for women in two communities in the Philippines: The importance of collecting site-specific data
81. Predicting severe head injury after light motor vehicle crashes: Implications for automatic crash notification systems
82. Using Models to Inform Policy: Insights from Modeling the Complexities of Global Polio Eradication
83. The Probability of Undetected Wild Poliovirus Circulation After Apparent Global Interruption of Transmission
84. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation
85. The role of risk analysis in polio eradication: modeling possibilities, probabilities and outcomes to inform choices
86. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019–2029
87. No Role for Reintroducing OPV into the United States with Respect to Controlling COVID‐19 [Response to the letter to the Editor by Chumakov et al.]
88. An Updated Economic Analysis of the Global Polio Eradication Initiative
89. Modeling and Managing Poliovirus Risks: We are Where we are…
90. Poliovirus vaccine options: another step forward
91. Using Animated Probability Plots to Explore the Suitability of Mixture Models with Two Component Distributions
92. Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain
93. Value of Biopsy in a Cohort of Children with High-Titer Celiac Serologies: Observation of Dynamic Policy Differences between Europe and North America
94. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID‐19 in the United States
95. Valuing health outcomes: developing better defaults based on health opportunity costs
96. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV
97. Potential Future Use, Costs, and Value of Poliovirus Vaccines
98. Updated Characterization of Post‐OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart
99. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
100. An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.